Infasurf Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Infasurf market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to an increase in premature births, the expansion of healthcare infrastructure, rising awareness of respiratory diseases, higher birth rates, and greater government initiatives aimed at reducing infant mortality rates.

The growth projected for the forecast period can be attributed to the increasing use of personalized medicine, rising air pollution levels, the growing incidence of neonatal respiratory diseases, a heightened focus on preventive care, and rapid urbanization. Key trends in the forecast period include the development of advanced neonatal respiratory treatments, innovations in non-invasive monitoring technologies for premature infants, a greater emphasis on early diagnosis and intervention, integration of telemedicine for remote care of infants, and the use of artificial intelligence in predicting respiratory conditions and treatment outcomes.

The growing prevalence of premature births is expected to drive the expansion of the infasurf market in the coming years. Premature birth, or preterm birth, occurs when a baby is born before 37 weeks of gestation, compared to the typical full-term delivery at around 40 weeks. This condition can lead to various health complications for the infant, such as respiratory problems, developmental delays, and an increased risk of long-term disabilities. Several factors contribute to the rise in premature births, including older maternal age, increased use of assisted reproductive technologies that lead to multiple pregnancies, and the impact of chronic health conditions and infections during pregnancy. Infasurf (calfactant) is administered directly into the lungs of premature infants to treat or prevent respiratory distress syndrome (RDS) by reducing surface tension and improving lung function. For instance, according to a report from the University of Bristol published in October 2024, approximately one in 13 births is preterm in the UK, totaling over 50,000 cases annually. Despite preventive measures, the rate of preterm births continues to rise. Additionally, the March of Dimes reported in March 2024 that the United States recorded 373,902 preterm births in 2023, representing 10.4% of all live births. This increasing prevalence of premature births is driving the growth of the infasurf market.

Rising healthcare spending is expected to contribute to the growth of the infasurf market in the future. Healthcare spending refers to the financial resources allocated by individuals, governments, private insurers, and other entities for healthcare services and products. This increase in spending is driven by factors such as an aging population, advancements in medical technology, a rise in chronic diseases, and a growing demand for healthcare services. Infasurf helps reduce the financial burden associated with extended hospital stays and complex respiratory interventions for premature infants with respiratory distress syndrome, making neonatal care more cost-effective. For example, healthcare spending in the UK increased by 5.6% from 2022 to 2023, with total healthcare expenditure reaching $317.63 billion (£292 billion), according to the Office for National Statistics. As healthcare expenditure rises, it is expected to further fuel the growth of the infasurf market.

The increasing awareness of infant respiratory disorders is factor driving the growth of the infasurf market. Infant respiratory disorders refer to conditions that affect the breathing and lung function of newborns, often due to underdeveloped lungs or complications during birth. The prevalence of these disorders is rising due to factors such as increasing premature birth rates, maternal health issues, environmental factors, higher cesarean delivery rates, and improved detection and diagnosis through advanced medical technologies. Infasurf, a surfactant replacement therapy, helps treat respiratory disorders by improving lung function and oxygenation in premature infants with respiratory distress syndrome, enhancing their ability to expand their lungs and exchange gases effectively. For example, in September 2024, the Centers for Disease Control and Prevention (CDC) reported that 58,000 to 80,000 children under five are hospitalized annually in the U.S. due to respiratory syncytial virus (RSV) infection, with infants being at the highest risk. Additionally, in July 2023, the National Library of Medicine reported that neonatal respiratory distress syndrome affects approximately 24,000 infants annually in the U.S., with 98% of infants born at 24 weeks gestation impacted. This rising awareness of infant respiratory disorders is driving the growth of the infasurf market.

The key company operating in the infasurf market is ONY Biotech Inc.

North America was the largest region in the infasurf market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in infasurf report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the infasurf market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Infasurf is a natural surfactant primarily used to treat respiratory distress syndrome in premature infants. Derived from bovine lungs, it contains phospholipids, including dipalmitoyl phosphatidylcholine, which reduce surface tension in the lungs, thereby improving gas exchange.

The primary patient demographics for infasurf include premature infants, full-term infants, and various age groups. Premature infants, born before 37 weeks of gestation, often have underdeveloped organs, especially the lungs. Infasurf is used to prevent or treat respiratory distress syndrome in these infants by boosting lung surfactant levels. It is distributed through multiple channels, including hospitals, specialty clinics, online pharmacies, and retail pharmacies. Key applications include treating neonatal respiratory distress syndrome and other respiratory conditions.

The infasurf market research report is one of a series of new reports that provides infasurf market statistics, including the infasurf industry's global market size, regional shares, competitors with an infasurf market share, detailed infasurf market segments, market trends and opportunities, and any further data you may need to thrive in the infasurf industry. This infasurf market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The infasurf market consists of sales of infasurf 3 ml intratracheal suspension. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.